All In Biotech

Drug Trial Radar · NCT06749457

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

A Phase I/IIa Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Participants and in Patients With End-stage Kidney Disease Receiving Hemodialysis Through a Central Venous Catheter

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 242 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

242

Actual

Start

Dec 30, 2024

Primary completion

Mar 8, 2027

Study completion Dec 13, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Dec 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).

Conditions

  • Staphylococcus Aureus

Interventions

  • AZD7760Drug

    Participants will receive AZD7760 as a single intravenous infusion.

  • PlaceboOther

    Participants will be administered placebo through intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Occurence of adverse events (AEs)Time frame: Day 1 to Day 181
  2. Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)Time frame: Day 1 to Day 361
  3. Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIsTime frame: Day 1 to Day 181

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Chula Vista, California

  • Research Site

    Glendale, California

  • Research Site

    Granada Hills, California

  • Research Site

    Los Angeles, California

  • Research Site

    Northridge, California

  • Research Site

    Northridge, California

  • Research Site

    Oxnard, California

  • Research Site

    Riverside, California

  • Research Site

    San Dimas, California

  • Research Site

    Tarzana, California

  • Research Site

    Valencia, California

  • Research Site

    Victorville, California

  • Research Site

    Englewood, Colorado

  • Research Site

    Bradenton, Florida

  • Research Site

    Coral Springs, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Lawrenceville, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Chicago, Illinois

  • Research Site

    Iowa City, Iowa

  • Research Site

    Lexington, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    Pontiac, Michigan

  • Research Site

    Tupelo, Mississippi

  • Research Site

    Kansas City, Missouri

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Jersey City, New Jersey

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Ridgewood, New York

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Bethlehem, Pennsylvania

  • Research Site

    Beaumont, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    McAllen, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.